Drug Pipeline

ALKS 2680 Dose 1 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
3
Recruiting
3
Phase 3
1
Top Sponsors
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-11 NCT07502443
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2		 Trial sites expanded: 8 -> 15 locations
2026-06-11 NCT07540897
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With…		 Trial sites expanded: 1 -> 5 locations
2026-06-05 NCT07455383
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1		 Trial sites expanded: 9 -> 17 locations
2026-05-16 NCT07540897
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With…		 Recruitment opened
Active Studies by Phase
Phase 3
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07455383 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 Narcolepsy Type 1 Recruiting
NCT07502443 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 Narcolepsy Type 2 Recruiting
NCT07540897 A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With… Narcolepsy Type 1 Recruiting
Sponsors Running ALKS 2680 Dose 1 Trials
Alkermes, Inc. (3)
Get alerts when ALKS 2680 Dose 1 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free